跳至主要内容
临床试验/NCT05898698
NCT05898698进行中(未招募)不适用

Prospective Observational Registry of Safety and Effectiveness of Acellular Fish Skin Grafts in Treatment of Cutaneous Wounds

Kerecis Ltd.1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2023年3月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Kerecis Ltd.
入组人数
300
试验地点
1
主要终点
Primary Endpoint : Complete Wound Closure

研究概览

简要总结

This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). The registry will be multi-center , target a wide patient population and a variety of wounds to document the quality of wound care, patient outcomes, safety and long-term results.

详细描述

Introduction: This registry will be conducted according to US standards of Good Clinical Practice as adopted by the Food and Drug Administration, associated Federal regulations and applicable institutional research policies and procedures. This study has been approved by a central IRB, WCG IRB in April 2023.

Registry Objectives: The overall objective of the registry is to collect quality and safety data to assess the efficacy of the FSG in treatment of acute and chronic wounds. The ultimate goal of the registry is to enhance quality of care, patient outcomes and establish a resource to facilitate the use of FSG in treatment of acute and chronic wounds.

Primary Objective: The main purpose of the registry is to evaluate the safety and long-term effectiveness of acellular fish skin grafts in treatment of acute and chronic wounds in a real world setting.

Secondary Objective: To evaluate the clinical and financial benefits of FSG in terms of quality of healing, pain and treatment cost.

Research Design: This registry will prospectively collect data from treatment and follow-up of patients who have undergone procedures where wounds are treated with Kerecis FSG. The registry is a non-experiment, multi-center , single arm, open label study to determine real world long-term safety and quality of Kerecis FSG. The study will not be interventional, de-indentified, HIPAA compliant data will only be collected on patients already scheduled to receive the Kerecis product. Subjects will be enrolled as they are scheduled to receive FSG for treatment of their index wound. Subjects will complete follow up as scheduled by their physician and their data will be documented at weekly follow-ups through week 32. Clinical improvement will be collected through case report forms (CRF) at each time point. Subjects will be followed for the 32 weeks but if the Index wound heals before that time , there will be a Healing Confirmation Visit (HCV) 2 weeks after to confirm the Index wound is still healed. If Index wound is not healed at the HCV then the subject will continue to next weekly visit. Index wound assessments will be captured digitally. The depth of the index wound will be collected manually by using a sterilized cotton swab placed in the deepest part of the wound and documenting that measurement. One year form the procedure, patients will receive a survey to evaluate their overall experience and provide any feedback. Overall, the registry is prospective except information regarding patient medical history can be collected retrospectively.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects age 18 and older and are able to provide informed consent.
  • Having at least one partial or full thickness wound appropriate for FSG and the wound has NOT received FSG previously.
  • Appropriate wounds include: Partial or full thickness wounds, Diabetic foot ulcers, venous leg ulcers, pressure ulcers, chronic vascular ulcers, Trauma wounds (2nd degree burn, abrasions, lacerations, skin tears.
  • Surgical wounds (donor sites/grafts, post-Mohs surgery, post Laser surgery, podiatric, wound dehiscence

排除标准

  • Patient has a 3rd degree burn Patient has a know sensitivity to fish products Patient whose target wound was previously treated with FSG Patient is breastfeeding

结局指标

主要结局

Primary Endpoint : Complete Wound Closure

时间窗: 32 weeks

Is time and frequency of complete wound closure by or on 32 weeks. Complete closure is referred to as full epithelialization with the absence of drainage.

次要结局

  • Reduction in wound depth(32 weeks)
  • Pain medication use(32 weeks)
  • Secondary Endpoints : Reduction in wound area(32 weeks)
  • Increase in Vascularization(32 weeks)
  • Readmission rate(32 weeks)
  • Number of applications/Cost(32 weeks)
  • I year follow-up(12 months)

研究者

发起方
Kerecis Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验